AU2002233928A1 - Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases - Google Patents

Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases

Info

Publication number
AU2002233928A1
AU2002233928A1 AU2002233928A AU3392802A AU2002233928A1 AU 2002233928 A1 AU2002233928 A1 AU 2002233928A1 AU 2002233928 A AU2002233928 A AU 2002233928A AU 3392802 A AU3392802 A AU 3392802A AU 2002233928 A1 AU2002233928 A1 AU 2002233928A1
Authority
AU
Australia
Prior art keywords
cycloalkylfused
spla2
inhibitors
treatment
inflammatory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002233928A
Inventor
Douglas Wade Beight
Michael Dean Kinnick
Ho-Shen Lin
John Michael Junior Morin
Michael Enrico Richett
Daniel Jon Sall
Jason Scott Sawyer
Edward C. R. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002233928A1 publication Critical patent/AU2002233928A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002233928A 2000-12-18 2001-12-06 Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases Abandoned AU2002233928A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25639700P 2000-12-18 2000-12-18
US60/256,397 2000-12-18
PCT/US2001/043187 WO2002050030A2 (en) 2000-12-18 2001-12-06 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
AU2002233928A1 true AU2002233928A1 (en) 2002-07-01

Family

ID=22972097

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002233928A Abandoned AU2002233928A1 (en) 2000-12-18 2001-12-06 Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases

Country Status (6)

Country Link
US (1) US6974831B2 (en)
EP (1) EP1349834A2 (en)
JP (1) JP2004518658A (en)
AU (1) AU2002233928A1 (en)
CA (1) CA2430808A1 (en)
WO (1) WO2002050030A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1747014A4 (en) * 2004-05-03 2007-09-12 Ilypsa Inc Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
WO2007056280A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors
MX2008005666A (en) * 2005-11-03 2009-03-02 Ilypsa Inc Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors.
WO2007056275A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors
MX2008005662A (en) * 2005-11-03 2008-12-15 Ilypsa Inc Azaindole compounds and use thereof as phospholipase-a2 inhibitors.
EP1951315A2 (en) * 2005-11-03 2008-08-06 Ilypsa, Inc. Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
ATE543808T1 (en) * 2006-12-22 2012-02-15 Schering Corp 5,6-RING-ANNELATED INDOLE DERIVATIVES AND USE THEREOF
BRPI0720625A2 (en) 2006-12-22 2014-03-25 Schering Corp 4,5-RING INDOL DERIVATIVES AND METHODS OF USE
AU2007339386B8 (en) * 2006-12-22 2013-12-05 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
EP2408761B1 (en) * 2007-08-29 2014-01-01 Merck Sharp & Dohme Corp. Substituted indole derivatives and methods of use thereof
CA2697500A1 (en) * 2007-08-29 2009-03-12 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
CN101842353A (en) * 2007-08-29 2010-09-22 先灵公司 2, 3-substituted indole derivatives for treating viral infections
CA2705587A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
CA2705586A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
AR072088A1 (en) * 2008-06-13 2010-08-04 Schering Corp TRICYCLE INDOL DERIVATIVES AND THEIR METHODS OF USE
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2024020534A2 (en) * 2022-07-22 2024-01-25 Schrödinger, Inc. Cyclic compounds and methods of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0690843B1 (en) * 1993-03-25 2000-08-30 PHARMACIA & UPJOHN COMPANY Formyl- or cyano- substituted indole derivatives having dopaminergic activity
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
US6325991B1 (en) 1998-08-24 2001-12-04 Susan E. Draheim Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
US6140327A (en) 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
US6831095B1 (en) * 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors

Also Published As

Publication number Publication date
JP2004518658A (en) 2004-06-24
CA2430808A1 (en) 2002-06-27
WO2002050030A2 (en) 2002-06-27
WO2002050030A8 (en) 2003-11-13
WO2002050030A3 (en) 2002-09-12
EP1349834A2 (en) 2003-10-08
US20040077704A1 (en) 2004-04-22
US6974831B2 (en) 2005-12-13

Similar Documents

Publication Publication Date Title
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
PL348059A1 (en) Compounds useful in the treatment of inflammatory diseases
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2001288271A1 (en) Methods for treating inflammatory diseases
AU2001272849A1 (en) Composition for the treatment of osteoarthritis
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
AU2002233928A1 (en) Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
AU2001272852A1 (en) Composition for the treatment of migraine
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU2001227972A1 (en) Methods to treat alpha-1-antitrypsin deficiency
AU2001260834A1 (en) The treatment of herpes
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2002309180A1 (en) Composition and kit for the treatment of inflammatory bowel diseases
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
AU2002365093A1 (en) Therapeutic compositions
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
AU3064800A (en) The therapeutic use of r-warfarin as anticoagulant
AU2002221566A1 (en) Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders